ERBB2 and cancer: Trastuzumab can inhibit the dimerization of HER-2 protein, suppress the transduction of downstream signals, increase the apoptosis of cancer cells, reduce DNA repair and hinder angiogenesis in HER-2+ BC [6, 7].